FDA schedules joint advisory committee meeting to consider first over-the-counter birth control pill
The FDA has set a date to review what could become the first over-the-counter birth control pill approved for use in the US.
HRA Pharma, recently acquired by Dublin-based Perrigo, filed back in July to make its daily progestin-only Opill available without a prescription. On Monday, the regulatory agency scheduled a joint meeting of its Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee to review the application on Nov. 18 from 9 am to 5:30 pm ET.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
